drugset
drugset / Trial / NCT04741061

Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light

NCT04741061 ↗

Phase 3 Unknown 6000 enrolled Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation CRO: iPharma · collabGovernment of the city of Moscow · collabRussian Direct Investment Fund · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same medical product under similar protocols. The key objective of this study is to be conducted in several parallel studies of the same vaccine above the other countries. Using similar protocols on a portfolio basis of studies let us collect data for Efficacy, Immunogenicity, Safety and Tolerability confirmation of the Sputnik-Light vaccine.

Timeline

Start
2021-02-19
Primary completion
2021-12-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sputnik Light Vaccine 1e+11 unknown —

Indications

No indication recorded.